# US 11,110,161 B2 · Vaccine for prophylaxis or treatment of an allergen-driven airway pathology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,161 B2
- Document ID: US11110161B2
- Status: Granted
- Kind: B2
- Application number: 16/840,276
- Filed: 2020-04-03
- Published: 2020-09-10
- Granted: 2021-09-07
- Earliest claimed: 2009-04-28
- Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM); Institut Pasteur de Lille; National University of Ireland Maynooth
- Inventors: Camille Locht; Bernard Mahon; Heather Kavanagh
- Web page: https://patentgrep.com/patent/US11110161B2

## CPC

- A61K 39/099: {Bordetella}
- A61P 31/04: Antibacterial agents
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/543: {intranasal}
- A61K 2039/544: {to the airways}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

## Claims

### Claim 1

A method of reducing allergen-driven lung eosinophilia in a subject with asthma, the method comprising the step of infecting the subject's respiratory tract with a live attenuated Bordetella pertussis strain which is deficient in tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT).

### Claim 2 (depends on 1)

The method of claim 1, wherein the strain comprises a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic (dnt) gene, and a heterologous ampG gene.

### Claim 3 (depends on 2)

The method of claim 2, wherein the heterologous ampG gene is an E. coli ampG gene that replaces the wild-type Bordetella strain ampG gene.

### Claim 4 (depends on 2)

The method of claim 2, wherein the mutation of the ptx gene comprises a substitution of an amino acid involved in substrate binding and/or an amino acid involved in catalysis.

### Claim 5 (depends on 4)

The method of claim 4, wherein the substitution of the amino acid involved in substrate binding comprises R9K and the substitution of the amino acid involved in catalysis comprises E129G.

### Claim 6 (depends on 2)

The method of claim 2, wherein the heterologous ampG gene is the only heterologous gene in the strain.